学术周报 · IF≥10

消化内科领域文献阅读汇编

2026年第39周 (2026-09-23) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
11
临床研究
6
基础研究
5
IF≥20
6
IF 10-20
5
子领域
9
期刊种类
10
数据日期
2026-09-23

★本周 Top 10 高影响力文献

#论文期刊IF
1Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intel...Nature medicineIF 52.5
2Glutamine metabolism as a rheostat of CD4+ T cell pathogenic function in metabolic dysfunction-assoc...Cell metabolismIF 37.0
3Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral ...Nature biomedical engineeringIF 26.3
4Steatotic Liver Disease Risk Scores to Predict Cirrhosis and Hepatocellular Carcinoma.JAMA internal medicineIF 26.3
5Prior endoscopic surveillance and diagnosis of Barrett-related dysplasia and cancer: evidence from a...GutIF 24.6
6High rates of transition to immune active disease in a cohort of strictly defined immune tolerant pa...GutIF 24.6
7Pharmacotherapy of Irritable Bowel Syndrome with Constipation in Children: An Update on Clinical Pro...DrugsIF 14.7
8SurgDepth: Test-Time Adaptation of Depth Foundation Models for Surgical Scene Understanding.IEEE transactions on medical imagingIF 12.4
9Diagnostic performance of the Japan Narrow-Band Imaging Expert Team and pit pattern classifications ...EndoscopyIF 11.8
10Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.Journal for immunotherapy of cancerIF 11.7

Ŧ期刊分布统计

期刊篇数IF
Gut2IF 24.6
Drugs1IF 14.7
Nature medicine1IF 52.5
Nature biomedical engineering1IF 26.3
JAMA internal medicine1IF 26.3
Journal for immunotherapy of cancer1IF 11.7
Cell metabolism1IF 37.0
Acta pharmacologica Sinica1IF 10.4
Endoscopy1IF 11.8
IEEE transactions on medical imaging1IF 12.4

1肝炎(病毒性/自免) (2篇)

临床研究 (1篇)

Gut IF 24.6 2026-9-18 PMID: 42760116
Patients with immune tolerant (IT) chronic hepatitis B (CHB) have high viral loads, minimal inflammation and minimal fibrosis. Nevertheless, the benign nature of this phase and the need for antiviral therapy remain controversial. We explored the natural history of IT patients by assessing the risk of transition to immune active (IA) disease, fibrosis progression and hepatocellular carcinoma (HCC). This international multicentre study from the RADICAL consortium includes mono-infected patients with CHB from sites around the world. The IT-phase was strictly defined as persistently (1) hepatitis B e-antigen (HBeAg)-positive, (2) alanine aminotransferase (ALT) ≤40 U/L, (3) HBV DNA >7 log10 IU/mL and (4) F0-1 during the first year after baseline. We assessed the probabilities of transition to IA disease (ALT ≥50 U/L), the risk of significant fibrosis (≥F2) and HCC. In total, 951 IT patients were included with a median age of 33, 40% were male with a median follow-up of 13 years. Median ALT and HBV DNA at baseline were 25.5 U/L and 8.4 log10 IU/mL.The probability of transitioning to IA disease was 51%, 67% and 72% before 5 years, 10 years and 15 years. A high-normal ALT was associated with an increased risk of IA disease (subdistribution hazard ratio (sHR): 20-30 U/L: 1.744, p<0.001, sHR: >30U/L: 3.130, p<0.001). IT patients had a low risk of progression to significant fibrosis (15 years: 6.3%), and HCC (15 years: 1.1%). The majority of this large cohort of well-defined IT patients transition to IA disease within 5 years of follow-up, with the highest risk observed in those with a high-normal ALT, suggesting that these patients may benefit from either more frequent monitoring or pre-emptive therapy.
中文摘要:免疫耐受(IT)期慢性乙型肝炎(CHB)患者具有高病毒载量、轻微炎症和轻微纤维化。然而,该期的良性性质以及是否需要抗病毒治疗仍存在争议。我们通过评估向免疫活动(IA)期疾病转变的风险、纤维化进展和肝细胞癌(HCC)风险,探讨IT期患者的自然史。这项来自RADICAL联盟的国际多中心研究纳入了世界各地中心的CHB单感染患者。IT期被严格定义为基线后第一年内持续满足:(1) 乙型肝炎e抗原(HBeAg)阳性,(2) 丙氨酸氨基转移酶(ALT)≤40 U/L,(3) HBV DNA >7 log10 IU/mL,(4) F0-1。我们评估了向IA期疾病(ALT ≥50 U/L)转变的概率、显著纤维化(≥F2)和HCC的风险。共纳入951例IT期患者,中位年龄33岁,40%为男性,中位随访13年。基线的中位ALT和HBV DNA分别为25.5 U/L和8.4 log10 IU/mL。向IA期疾病转变的概率在5年、10年和15年时分别为51%、67%和72%。高正常ALT与IA期疾病风险增加相关(亚分布风险比(sHR):20-30 U/L:1.744,p<0.001;sHR:>30 U/L:3.130,p<0.001)。IT期患者进展为显著纤维化的风险低(15年:6.3%),HCC风险低(15年:1.1%)。在这个定义明确的大型IT期患者队列中,大多数患者在随访5年内转变为IA期疾病,其中高正常ALT者风险最高,提示这些患者可能从更频繁的监测或抢先治疗中获益。

基础研究 (1篇)

Nature biomedical engineering IF 26.3 2026-9-22 PMID: 42768130
Approved chronic hepatitis B therapies rarely result in functional cure, as they fail to permanently silence all transcriptionally active hepatitis B virus (HBV) DNA. CRMA-1001 employs an optimized epigenetic silencer that represses viral transcription through targeted deposition of DNA methylation on episomal and integrated HBV DNAs. Here we showed that in HBV mouse models, a single dose of CRMA-1001 produced >3-log10 reductions in viral biomarkers, which correlated with de novo methylation of HBV DNA. Three doses resulted in up to 90% of animals with undetectable hepatitis B surface antigen and HBV DNA by 6 months post treatment. In non-human primates, CRMA-1001 induced transient liver transaminase elevations only at the highest dose tested. Expression and DNA methylation profiling revealed no detectable unintended targets in the human genome. These findings support the initiation of clinical development of CRMA-1001 as a finite treatment course with the potential for functional cure in individuals living with chronic hepatitis B.
中文摘要:已获批的慢性乙型肝炎疗法很少实现功能性治愈,因为它们无法永久沉默所有具有转录活性的乙型肝炎病毒(HBV)DNA。CRMA-1001采用一种优化的表观遗传沉默子,通过在游离型和整合型HBV DNA上靶向沉积DNA甲基化来抑制病毒转录。本研究表明,在HBV小鼠模型中,单剂CRMA-1001使病毒生物标志物降低超过3个log10,且这与HBV DNA的从头甲基化相关。三剂给药后,截至治疗后6个月,多达90%的动物达到乙型肝炎表面抗原和HBV DNA检测不到。在非人灵长类动物中,CRMA-1001仅在测试的最高剂量下引起一过性肝转氨酶升高。表达和DNA甲基化谱分析显示,在人类基因组中未检测到非预期靶点。这些发现支持启动CRMA-1001的临床开发,将其作为一种有限疗程治疗,并有望为慢性乙型肝炎感染者带来功能性治愈。

2NAFLD/NASH/代谢肝病 (2篇)

临床研究 (1篇)

JAMA internal medicine IF 26.3 2026-9-21 PMID: 42766290
Most individuals with steatotic liver disease (SLD) do not develop advanced liver disease. Multiple risk scores for SLD-associated cirrhosis and hepatocellular carcinoma (HCC) have been proposed, but their utility to inform decisions about surveillance for advanced liver disease is unknown. To compare the clinical utility of SLD risk scores for predicting cirrhosis and hepatocellular carcinoma in patients with noncirrhotic steatotic liver disease. This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD without viral hepatitis or primary liver disease from 2008 and 2020. Nine clinical risk scores were calculated at the time of the first imaging results that demonstrated hepatic steatosis. Individuals were followed up until cirrhosis, HCC, death, or 6 months after last follow-up visit. Data were analyzed between November 1, 2025, and May 11, 2026. Nine risk scores evaluated for prediction of cirrhosis or HCC within 10 years were: (1) ALBI, albumin-bilirubin; (2) aMAP, age-male-albumin-bilirubin-platelet; (3) APRI, the aspartate aminotransferase-to-platelet ratio; (4) BARD, body mass index, age, alanine aminotransferase-to-aspartate aminotransferase ratio, and diabetes; (5) FIB-4, fibrosis-4 index; (6) NFS, nonalcoholic fatty liver disease fibrosis; (7) SAFE, steatosis-associated fibrosis estimator; and 2 additional scores. First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry. Cox proportional hazards models were used to calculate time-dependent 10-year probabilities of each outcome predicted by 9 risk scores. Decision curves were generated for each outcome by calculating the net benefit, a weighted measure of true and false positives over a prespecified range of risk thresholds at which a clinician may reasonably recommend intervention. Nine risk scales were used to quantify the risk of cirrhosis or HCC within 10 years. The analysis included 853 131 patients (median [IQR] age, 61 [51-68] years; 62 168 females [7.3%] and 790 965 males [92.7%]) whose median (IQR) BMI was 31.3 (27.6-35.5) and 275 898 (32.3%) had diabetes; of these, 33 794 (3.96%) developed cirrhosis and 2978 (0.35%) developed HCC within 10 years. The FIB-4, APRI, and SAFE scores demonstrated the greatest discrimination of cirrhosis risk, while the SAFE, Tate, and FIB-4 scores demonstrated the greatest discrimination of HCC risk. The SAFE score demonstrated the greatest net benefit predicting cirrhosis. A score of 29.5 corresponded to a 10-year cirrhosis risk of 2.5% and yielded a net benefit of 0.019, or 1.9 additional individuals who develop cirrhosis per 100 individuals classified as at-risk patients. At a 0.25% 10-year risk of HCC, the SAFE score had a net benefit of 0.0016 (1.6 additional true positives per 1000 individuals). The findings of this cohort study show that the SAFE score may inform decisions to repeat screening for cirrhosis in patients with SLD. Clinical risk scores for HCC demonstrated minimal utility to inform HCC screening decisions for patients with noncirrhotic SLD.
中文摘要:脂肪性肝病(SLD)患者中大多数不会发生晚期肝病。已提出多种用于SLD相关肝硬化和肝细胞癌(HCC)的风险评分,但其用于指导晚期肝病监测决策的价值尚不明确。本研究旨在比较SLD风险评分在非肝硬化脂肪性肝病患者中预测肝硬化和肝细胞癌的临床价值。这项队列研究使用了美国国家退伍军人事务部医疗系统的数据,纳入2008年至2020年经影像学确诊SLD、且无病毒性肝炎或原发性肝病的成人。在首次显示肝脂肪变的影像学结果时计算9种临床风险评分。随访至发生肝硬化、HCC、死亡或末次随访后6个月。数据分析时间为2025年11月1日至2026年5月11日。用于评估10年内肝硬化或HCC预测的9种风险评分为:(1)ALBI,白蛋白-胆红素;(2)aMAP,年龄-男性-白蛋白-胆红素-血小板;(3)APRI,天冬氨酸氨基转移酶与血小板比值;(4)BARD,体质指数、年龄、丙氨酸氨基转移酶与天冬氨酸氨基转移酶比值及糖尿病;(5)FIB-4,纤维化-4指数;(6)NFS,非酒精性脂肪性肝病纤维化;(7)SAFE,脂肪变相关纤维化估算器;以及另外2种评分。肝硬化首次诊断和HCC首次诊断通过VA和Medicare诊断代码以及VA癌症登记处数据确定。采用Cox比例风险模型计算9种风险评分预测的每种结局的时间依赖性10年概率。针对每种结局生成决策曲线,计算净获益,即在临床医生可能合理推荐干预的预设风险阈值范围内,对真阳性和假阳性进行加权的指标。使用9种风险评分量化10年内肝硬化或HCC风险。分析纳入853131例患者(中位[IQR]年龄61[51-68]岁;女性62168例[7.3%],男性790965例[92.7%]),中位[IQR]BMI为31.3[27.6-35.5],275898例(32.3%)患有糖尿病;其中,33794例(3.96%)在10年内发生肝硬化,2978例(0.35%)发生HCC。FIB-4、APRI和SAFE评分对肝硬化风险的区分度最大,而SAFE、Tate和FIB-4评分对HCC风险的区分度最大。SAFE评分预测肝硬化的净获益最大。评分为29.5对应10年肝硬化风险2.5%,净获益为0.019,即每100例被归为风险患者中,额外1.9例发生肝硬化。在10年HCC风险为0.25%时,SAFE评分的净获益为0.0016(每1000例中额外1.6例真阳性)。这项队列研究的发现表明,SAFE评分可能有助于SLD患者重复筛查肝硬化的决策。HCC临床风险评分对非肝硬化SLD患者HCC筛查决策的价值极小。

基础研究 (1篇)

Cell metabolism IF 37.0 2026-9-18 PMID: 42759512
Metabolic dysfunction-associated steatotic liver disease (MASLD) severity is independently linked with pathogenic CD4+ T cell responses and skewed hepatic glutamine (Gln) metabolism. Whether these processes interact to drive disease progression remains unclear. Here, we identify hepatic Gln depletion as a key feature of steatohepatitis that is linked with increased hepatic CD4+ T cell inflammation and hepatocellular damage in humans. In complementary mouse models, both total hepatic and hepatic CD4+ T cell Gln levels were similarly reduced. Restoration of hepatic Gln through supplementation selectively restrained hepatic CD4+ T cell inflammatory programs and alleviated hepatocellular damage and disease severity. Mechanistically, T cell-intrinsic Gls1-mediated glutaminolysis limited O-GlcNAcylation to dampen pathogenic CD4+ T cell inflammation. Importantly, Gln treatment dampened CD4+ T cell-mediated injury in human liver organoids. Together, these findings establish hepatic CD4+ T cell-intrinsic Gln metabolism as a critical rheostat of pathogenic inflammation in MASLD and invoke metabolism-targeted strategies to restrict disease progression.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)的严重程度与致病性CD4+ T细胞反应及肝脏谷氨酰胺(Gln)代谢偏移独立相关。这些过程是否相互作用以驱动疾病进展仍不清楚。在此,我们将肝脏Gln耗竭确定为脂肪性肝炎的一个关键特征,并且在人类中与肝脏CD4+ T细胞炎症增加和肝细胞损伤相关。在互补的小鼠模型中,肝脏总体和肝脏CD4+ T细胞Gln水平同样降低。通过补充恢复肝脏Gln可选择性地抑制肝脏CD4+ T细胞炎症程序,并减轻肝细胞损伤和疾病严重程度。机制上,T细胞内在的Gls1介导的谷氨酰胺分解限制了O-GlcNAcylation,从而抑制致病性CD4+ T细胞炎症。重要的是,Gln治疗减轻了人肝类器官中CD4+ T细胞介导的损伤。总之,这些发现确立了肝脏CD4+ T细胞内在Gln代谢是MASLD致病性炎症的关键调节器,并提示可采用靶向代谢的策略限制疾病进展。

3肠易激/IBS/功能性胃肠病 (1篇)

临床研究 (1篇)

Drugs IF 14.7 2026-9-23 PMID: 42773320
Irritable bowel syndrome with constipation is a prevalent disorder of gut-brain interaction in children and adolescents, associated with chronic abdominal pain, altered bowel habits, reduced quality of life, and a significant healthcare burden. Despite a wide range of therapeutic approaches, treatment responses remain suboptimal, highlighting the need for effective, evidence-based pharmacological options. This review summarizes current and emerging pharmacological therapies for pediatric irritable bowel syndrome with constipation, with a focus on their mechanisms of action, efficacy, and safety. Traditional treatments such as dietary fiber, probiotics, antispasmodics, laxatives, prokinetics, antidepressants, antibiotics, and antihistamines are reviewed, emphasizing the limited and often inconsistent evidence supporting their use for pain relief and overall symptom improvement. Particular attention is given to newer agents approved for adults with irritable bowel syndrome with constipation, including secretagogues (linaclotide, plecanatide, and lubiprostone) and the retainagogue tenapanor, with a detailed discussion of their pharmacological properties and clinical trial data. Linaclotide is currently the only medication approved by the U.S. Food and Drug Administration for the treatment of irritable bowel syndrome with constipation in children aged 7 years or older. While other novel agents have shown promise in adults, pediatric data remain limited or unavailable. Overall, although pharmacological treatment options for pediatric irritable bowel syndrome with constipation are expanding, high-quality, pediatric specific clinical trials are still needed to guide safe and effective management.
中文摘要:便秘型肠易激综合征是儿童和青少年中常见的肠-脑互动障碍,与慢性腹痛、排便习惯改变、生活质量下降以及显著的医疗负担相关。尽管治疗手段广泛,但治疗反应仍不理想,突显了对有效且基于证据的药物治疗选择的需求。本综述总结了当前及新兴的儿童便秘型肠易激综合征药物治疗,重点介绍其作用机制、疗效和安全性。文中回顾了膳食纤维、益生菌、解痉药、泻药、促动力药、抗抑郁药、抗生素和抗组胺药等传统治疗,强调支持其用于缓解疼痛和改善总体症状的证据有限且常不一致。特别关注已获批用于成人便秘型肠易激综合征的较新药物,包括促分泌剂利那洛肽、普卡那肽和鲁比前列酮,以及滞留剂替那帕诺,并详细讨论其药理学特性和临床试验数据。利那洛肽目前是美国食品药品监督管理局批准用于治疗7岁及以上儿童便秘型肠易激综合征的唯一药物。虽然其他新型药物在成人中显示出前景,但儿科数据仍然有限或缺乏。总体而言,尽管儿童便秘型肠易激综合征的药物治疗选择正在扩大,仍需要高质量、儿科特异性的临床试验来指导安全有效的管理。

4消化道早癌筛查 (1篇)

临床研究 (1篇)

Nature medicine IF 52.5 2026-9-23 PMID: 42773211
The absence of accurate, noninvasive, scalable screening tools keeps early esophageal cancer (EC) detection a global health challenge. Although noncontrast computed tomography (NC CT) is widely accessible, the esophagus is a hollow tubular structure prone to collapse and motion artifacts, making small early malignant lesions difficult to distinguish from normal tissue. Here we developed the Esophageal AI-Guided malignant Lesion Evaluation (EAGLE) model to detect precancerous lesions and cancer from chest NC CT, a task historically considered impossible. EAGLE was trained on 6,813 patients from two centers and validated across 12 centers in three countries involving 80,612 patients in opportunistic and population-based screening settings. For opportunistic screening on existing CT scans, multicenter external test cohorts (eight centers, n = 11,466) achieved 98.5% specificity, with 90.0% sensitivity for cancer and 52.5% for precancerous lesions; low-dose CT (LDCT) validation (two centers, n = 1,607) showed comparable performance, supporting EC screening through lung-cancer screening programs. Calibration in a real-world cohort (three centers, n = 35,402) reduced false positives by 72.7% while preserving sensitivity; prospective hospital validation (n = 17,446) achieved a 42.2% PPV, and real-world low-dose screening (n = 10,959) reached 99.94% specificity. EAGLE also detected precancerous lesions-in paired CT-endoscopy cohorts (two centers, n = 702), sensitivities were 65.0% for precancerous lesions and 78.4% for stage I EC at a higher-sensitivity operating point. Exploratory analyses of a prospectively enrolled cohort suggest that referring high-risk individuals for endoscopy could improve screening efficiency. In conclusion, EAGLE has the potential to serve as a scalable tool for early EC screening. Chictr.org.cn identifier: ChiCTR2300074806 .
中文摘要:缺乏准确、无创且可扩展的筛查工具,使早期食管癌(EC)检测仍是全球健康挑战。尽管非增强计算机断层扫描(NC CT)广泛可及,但食管为中空管状结构,易发生塌陷和运动伪影,使小的早期恶性病变难以与正常组织区分。在此,我们开发了食管人工智能引导恶性病变评估(EAGLE)模型,用于从胸部NC CT中检测癌前病变和癌症,这一任务历来被认为不可能完成。EAGLE在来自两个中心的6,813例患者中训练,并在三个国家12个中心、涉及80,612例患者的机会性筛查和人群筛查场景中验证。对于基于现有CT扫描的机会性筛查,多中心外部测试队列(8个中心,n=11,466)达到98.5%的特异度,对癌症的敏感度为90.0%,对癌前病变为52.5%;低剂量CT(LDCT)验证(两个中心,n=1,607)显示相当的性能,支持通过肺癌筛查项目进行EC筛查。在真实世界队列(三个中心,n=35,402)中的校准将假阳性减少72.7%,同时保持敏感度;前瞻性医院验证(n=17,446)达到42.2%的PPV,真实世界低剂量筛查(n=10,959)达到99.94%的特异度。EAGLE还在配对CT-内镜队列(两个中心,n=702)中检测到癌前病变;在较高敏感度操作点,癌前病变敏感度为65.0%,I期EC敏感度为78.4%。对前瞻性入组队列的探索性分析提示,将高风险个体转诊进行内镜检查可提高筛查效率。总之,EAGLE有潜力作为早期EC筛查的可扩展工具。Chictr.org.cn注册号:ChiCTR2300074806。

5GERD/食管疾病 (1篇)

临床研究 (1篇)

Gut IF 24.6 2026-9-21 PMID: 42767826
In patients with Barrett oesophagus (BE), surveillance aims to detect dysplasia or oesophageal adenocarcinoma (EAC) early. Whether most asymptomatic patients undergoing endoscopic treatment are identified through surveillance remains uncertain. To assess the contribution of surveillance to the diagnosis of dysplasia and cancer. Patients in the Netherlands with curative treatment for BE-related dysplasia or EAC between 2008 and 2018 were identified from the Barrett Expert Center Registry for endoscopic therapy and the Cancer Registry for surgery or chemoradiotherapy. Endoscopy history was based on pathology reports, with at least one endoscopy with non-dysplastic BE 1-5 years before treatment. Primary endpoint was the proportion of patients with dysplasia or EAC with and without ('de novo patients') prior endoscopies. In total, 8914 patients were included: 90% (95% CI 89% to 91%; 8025/8914) presented de novo, while 10% (95% CI 9% to 11%; 889/8914) had prior endoscopies (mean of 4/IQR 2-7). Overall, 65% had stage ≥II disease, mostly in the de novo group (stage ≥II: 70% de novo vs 11% with prior endoscopy; p<0.001). Two-thirds of endoscopically treated patients (65% (95% CI 62% to 67%); 1283/1989) presented de novo and 97% (95% CI 97% to 98%; 6742/6925) with non-endoscopic therapy. Among those with prior endoscopy, a low rate of missed advanced neoplasia was observed (11%; 96/889). In this nationwide cohort, 90% of patients with Barrett-related dysplasia and cancer and 65% undergoing organ-preserving endoscopic treatment had not undergone prior endoscopy. This underscores the need to evaluate whether targeted, evidence-based screening strategies can improve early detection and patient outcomes.
中文摘要:在 Barrett 食管(BE)患者中,监测旨在早期发现异型增生或食管腺癌(EAC)。大多数接受内镜治疗的无症状患者是否通过监测被发现仍不确定。评估监测对异型增生和癌诊断的贡献。2008 年至 2018 年间,在荷兰因 BE 相关异型增生或 EAC 接受根治性治疗的患者,分别从 Barrett 专家中心内镜治疗登记处和癌症登记处(针对手术或放化疗)中识别。内镜史基于病理报告,定义为治疗前 1-5 年至少一次显示非异型增生性 BE 的内镜检查。主要终点是有和无既往内镜检查(「de novo 患者」)的异型增生或 EAC 患者比例。共纳入 8914 例患者:90%(95% CI 89% 至 91%;8025/8914)为 de novo 就诊,而 10%(95% CI 9% 至 11%;889/8914)有既往内镜检查(平均 4 次/IQR 2-7)。总体而言,65% 为 ≥II 期疾病,主要见于 de novo 组(≥II 期:de novo 组 70% vs 有既往内镜组 11%;p<0.001)。接受内镜治疗的患者中,三分之二(65%(95% CI 62% 至 67%);1283/1989)为 de novo 就诊,而接受非内镜治疗者中 97%(95% CI 97% 至 98%;6742/6925)为 de novo。在有既往内镜检查者中,观察到漏诊晚期肿瘤的比例较低(11%;96/889)。在这项全国性队列中,90% 的 Barrett 相关异型增生和癌患者以及 65% 接受保留器官内镜治疗的患者既往未接受过内镜检查。这凸显出需要评估有针对性的、基于证据的筛查策略能否改善早期检测和患者结局。

6多发性骨髓瘤 (1篇)

基础研究 (1篇)

Journal for immunotherapy of cancer IF 11.7 2026-9-18 PMID: 42759984
In relapsed/refractory multiple myeloma, the approved B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell product ciltacabtagene autoleucel (cilta-cel) shows higher response rates than idecabtagene vicleucel (ide-cel) in pivotal trials and real-world comparisons. This advantage has been attributed to the biparatopic dual-VHH (dVHH) binder of cilta-cel. However, the products also differ in the gene regulatory elements driving CAR expression: cilta-cel uses a human elongation factor α (EF1α) promoter in conjunction with a woodchuck hepatitis post-transcriptional regulatory element (EF1α+WPRE), whereas ide-cel uses a myeloproliferative sarcoma virus enhancer (MND) promoter without WPRE (MMD-WPRE). The role of these elements in CAR-T cell efficacy remains unexplored.We generated lentiviral vectors where the CAR transgene was composed of either a dVHH-based or a single-chain variable fragment (scFv)-based BCMA-CAR with a 4-1BB costimulatory and a CD3ζ signaling domain, expressed either by EF1α+WPRE or MND-WPRE Primary human T cells or a nuclear factor of activated T cells (NFAT)-GFP Jurkat reporter line were compared at matched vector copy numbers (VCN) or CAR surface expression. Antitumor efficacy was assessed in MM.1S-engrafted NSG mice.When transduced at the same multiplicities of infection, MND-WPRE CAR-T cells reached higher VCN and transduction rates than EF1α+WPRE regardless of the binder type. In an NFAT-GFP reporter assay, unstimulated MND-WPRE-driven cells showed higher NFAT and CD69 expression, consistent with greater tonic signaling compared with EF1α+WPRE In vivo, independently of the BCMA binder moiety, EF1α+WPRE-driven CAR-T cells demonstrated superior cytokine secretion and tumor control along with greater survival of mice treated with EF1α+WPREcompared with MND-WPRE-driven CAR-T cells.CAR-T cells expressing the CAR under MND-WPRE showed greater gene transfer during manufacturing, but this did not translate into superior function in vivo. The advantage attributed to cilta-cel's dual VHH binder was lost when expressed under MND-WPRE and, conversely, ide-cel's scFv binder achieved better antitumor activity when expressed under EF1α+WPRE than under MND-WPRE The efficacy difference between our CAR constructs in xenograft models therefore tracked with the choice of regulatory elements driving CAR expression independently of the binder. It may be better to choose gene regulatory elements based on the CAR-T cell function they confer rather than on expression strength alone.
中文摘要:在复发/难治性多发性骨髓瘤中,已获批的靶向B细胞成熟抗原(BCMA)的嵌合抗原受体(CAR)-T细胞产品西达基奥仑赛(cilta-cel)在关键试验和真实世界比较中显示出比idecabtagene vicleucel(ide-cel)更高的缓解率。这一优势被归因于cilta-cel的双靶向双VHH(dVHH)结合域。然而,这些产品在驱动CAR表达的基因调控元件上也存在差异:cilta-cel使用人延伸因子α(EF1α)启动子并结合旱獭肝炎病毒转录后调控元件(EF1α+WPRE),而ide-cel使用不含WPRE的骨髓增殖性肉瘤病毒增强子(MND)启动子(MND-WPRE)。这些元件在CAR-T细胞疗效中的作用尚未得到探索。我们构建了慢病毒载体,其中CAR转基因由基于dVHH或基于单链可变片段(scFv)的BCMA-CAR组成,带有4-1BB共刺激域和CD3ζ信号域,并由EF1α+WPRE或MND-WPRE驱动表达。在匹配载体拷贝数(VCN)或CAR表面表达的条件下,比较了原代人T细胞或核因子活化T细胞(NFAT)-GFP Jurkat报告细胞系。在植入MM.1S的NSG小鼠中评估抗肿瘤疗效。当以相同感染复数转导时,无论结合域类型如何,MND-WPRE CAR-T细胞均比EF1α+WPRE达到更高的VCN和转导率。在NFAT-GFP报告基因试验中,未刺激的MND-WPRE驱动细胞显示出更高的NFAT和CD69表达,与EF1α+WPRE相比,这与更强的强直性信号一致。在体内,与MND-WPRE驱动的CAR-T细胞相比,EF1α+WPRE驱动的CAR-T细胞表现出更优的细胞因子分泌和肿瘤控制,并伴有接受EF1α+WPRE治疗小鼠更长的生存期,且这一结果与BCMA结合域部分无关。在MND-WPRE下表达CAR的CAR-T细胞在生产过程中显示出更高的基因转移,但这并未转化为更优的体内功能。当在MND-WPRE下表达时,归因于cilta-cel双VHH结合域的优势消失;相反,ide-cel的scFv结合域在EF1α+WPRE下表达时比在MND-WPRE下表达获得更好的抗肿瘤活性。因此,我们的CAR构建体在异种移植模型中的疗效差异与驱动CAR表达的调控元件选择相关,而与结合域无关。选择基因调控元件时,或许最好根据其赋予的CAR-T细胞功能,而不是仅依据表达强度。

7多种肝病 (1篇)

基础研究 (1篇)

Acta pharmacologica Sinica IF 10.4 2026-9-18 PMID: 42754702
Liver diseases are hepatic pathological changes caused by a variety of pathogenic factors, including viral hepatitis, alcoholic liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), cirrhosis, and hepatocellular carcinoma (HCC), etc. The characteristics of liver diseases are steatosis, hepatocyte ballooning, and immune cell infiltration. Among these immune cells, neutrophils are important immune cells in innate immunity. Under hepatic pathological conditions, neutrophils can produce neutrophil extracellular traps (NETs) under the stimulation of various factors, such as viral infections, metabolic disorders, toxic exposures, etc. Accumulating evidence has shown that NETs can interact with multiple signaling pathways and immune cells, regulate hepatic inflammatory responses, remodel the hepatic immune microenvironment, and promote the activation of hepatic stellate cells (HSCs). This review expounds the mechanism of NETs in various liver diseases, and the compounds or drugs that have been discovered or applied for the treatment of liver diseases by targeting NETs. This review enriches the pathogenesis of liver diseases and provides a theoretical basis and research directions for targeted therapeutic strategies.
中文摘要:肝病是由多种致病因素引起的肝脏病理改变,包括病毒性肝炎、酒精性肝病(ALD)、代谢功能障碍相关脂肪性肝病(MASLD)、肝硬化和肝细胞癌(HCC)等。肝病的特征是脂肪变性、肝细胞气球样变和免疫细胞浸润。在这些免疫细胞中,中性粒细胞是先天免疫中的重要免疫细胞。在肝脏病理条件下,中性粒细胞可在病毒感染、代谢紊乱、毒性暴露等多种因素刺激下产生中性粒细胞胞外诱捕网(NETs)。越来越多证据表明,NETs可与多种信号通路和免疫细胞相互作用,调节肝脏炎症反应,重塑肝脏免疫微环境,并促进肝星状细胞(HSCs)活化。本综述阐述了NETs在多种肝病中的机制,以及已发现或应用于通过靶向NETs治疗肝病的化合物或药物。本综述丰富了肝病的发病机制,并为靶向治疗策略提供了理论基础和研究方向。

8结直肠息肉 (1篇)

临床研究 (1篇)

Endoscopy IF 11.8 2026-9-17 PMID: 42753802
Background and study aims Optical diagnosis of small colorectal lesions is important for the potential implementation of "resect-and-discard" and "leave-in-situ" strategies. We evaluated the performance of the Japan Narrow-Band Imaging Expert Team (JNET) and pit pattern classifications in differentiating small adenomatous and serrated colorectal lesions using a modern high-definition endoscopy system (EVIS X1), with outcomes stratified by endoscopist expertise. Patients and methods This secondary analysis of the prospective multicenter deTXIon trial included 1,830 colorectal lesions for JNET evaluation, of which 92.9% measured <10 mm, and 1,601 lesions for pit pattern evaluation. Adenocarcinomas were excluded. Sensitivity, specificity, positive and negative predictive values, and likelihood ratios were calculated. To account for multiple lesions within the same patient, 95% confidence intervals (CIs) were estimated using a cluster bootstrap approach with patients as the resampling unit. Exploratory expert-non-expert differences in sensitivity, specificity, and negative predictive value were also estimated. Results JNET showed high diagnostic performance, with no clear between-group differences in sensitivity, specificity, or negative predictive value. For pit pattern classification, expert-non-expert differences were 5.01 percentage points for sensitivity (95% CI, 1.23-9.08) and 10.00 percentage points for negative predictive value (95% CI, 1.37-18.56). Conclusions JNET showed similar observed diagnostic performance across expertise levels, whereas pit pattern classification showed greater between-group differences in sensitivity and negative predictive value. These findings suggest that JNET may serve as a practical framework for routine optical diagnosis of small lesions.
中文摘要:背景与研究目的:小结直肠病变的光学诊断对于潜在实施「切除并丢弃」和「原位保留」策略具有重要意义。我们使用现代高清内镜系统(EVIS X1)评估日本窄带成像专家团队(JNET)分类和pit pattern分类在区分小腺瘤性和锯齿状结直肠病变中的表现,并按内镜医师经验分层分析结果。患者与方法:这项前瞻性多中心deTXIon试验的二次分析纳入1,830个结直肠病变用于JNET评估,其中92.9%病变小于10 mm,另有1,601个病变用于pit pattern评估。腺癌被排除。计算敏感性、特异性、阳性预测值、阴性预测值和似然比。为考虑同一患者内多个病变,采用以患者为重抽样单位的聚类bootstrap方法估计95%置信区间(CI)。还探索性估计专家与非专家在敏感性、特异性和阴性预测值方面的差异。结果:JNET显示出高诊断性能,在敏感性、特异性或阴性预测值方面未见明确的组间差异。对于pit pattern分类,专家与非专家的差异为敏感性5.01个百分点(95% CI,1.23-9.08)和阴性预测值10.00个百分点(95% CI,1.37-18.56)。结论:JNET在不同经验水平间显示出相似的观察诊断性能,而pit pattern分类在敏感性和阴性预测值方面显示出更大的组间差异。这些发现提示JNET可作为小病变常规光学诊断的实用框架。

9内镜/ESD/ERCP (1篇)

基础研究 (1篇)

IEEE transactions on medical imaging IF 12.4 2026-9-17 PMID: 42752422
Accurate depth estimation from endoscopic images is fundamental to surgical navigation, augmented reality, and robotic assistance, yet depth foundation models trained on natural images degrade severely on surgical endoscopy, and existing adaptation methods require surgical training data for each new camera and clinical environment. We propose SurgDepth, a test-time adaptation (TTA) framework that adapts pre-trained depth foundation models to surgical endoscopy without any labeled surgical data. SurgDepth combines two self-supervised signals-stereo photometric consistency for rectified stereo pairs, and flip equivariance requiring only single images-with selective decoder adaptation and two tuning-free reliability mechanisms: a progress-aware anchor regularization and a structural-trust safeguard for poorly-illuminated sequences. Through the first systematic study of TTA for dense depth regression (eight baselines), we show that existing TTA methods consistently fail in this setting: entropy-based methods degrade regardless of the number of adapted parameters, and temporal-photometric adaptation diverges on non-rigid tissue. SurgDepth reduces AbsRel by up to 63% with stereo pairs and 42% without, improves four of five cross-domain evaluation settings (three of four unseen datasets; Hamlyn is evaluated under two protocols), generalizes across seven foundation models, and attains the lowest AbsRel (0.128) on the complete standard Hamlyn benchmark among all reported methods. All results evaluate relative (median-scaled) depth; 20-step convergence (0.4 s) makes SurgDepth practical for relative-depth applications such as augmented-reality overlay and reconstruction initialization.
中文摘要:从内镜图像中准确估计深度是手术导航、增强现实和机器人辅助的基础,然而在自然图像上训练的深度基础模型在外科内镜场景中会严重退化,且现有适配方法需要针对每个新相机和临床环境提供外科训练数据。我们提出 SurgDepth,一种测试时适配(TTA)框架,可在没有任何标注外科数据的情况下,将预训练深度基础模型适配到外科内镜场景。SurgDepth 结合了两种自监督信号——用于校正立体图像对的立体光度一致性,以及仅需单张图像的翻转等变性——并采用选择性解码器适配和两种无需调参的可靠性机制:进度感知锚点正则化和针对光照不良序列的结构信任保护机制。通过对稠密深度回归的 TTA 进行首个系统性研究(八个基线),我们表明现有 TTA 方法在此设定下持续失败:基于熵的方法无论适配参数数量多少都会退化,而时序光度适配在非刚性组织上会发散。SurgDepth 在使用立体图像对时将 AbsRel 最多降低 63%,不使用立体图像对时降低 42%,在五个跨域评估设定中的四个上取得改进(四个未见数据集中的三个;Hamlyn 在两种协议下评估),可泛化到七种基础模型,并在完整的标准 Hamlyn 基准上取得所有已报道方法中最低的 AbsRel(0.128)。所有结果均评估相对(中位数缩放)深度;20 步收敛(0.4 秒)使 SurgDepth 适用于增强现实叠加和重建初始化等相对深度应用。